This Week’s CGT News: CRISPR Hits Phase 3 Milestone - Takeaways - MDSpire
Clinical Guidelines

This Week’s CGT News: CRISPR Hits Phase 3 Milestone

Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal

  • May 4, 2026

  • 7 min

Share

  • 1

    Intellia's lonvo-z therapy reduced HAE attacks by 87%.

  • 2

    The therapy inactivates the KLKB1 gene.

  • 3

    62% of patients were attack-free without medication.

  • 4

    Favorable safety profile with mild adverse events.

  • 5

    Biologics license application to FDA planned for 2027.

Original Source(s)

This Week’s CGT News: CRISPR Hits Phase 3 Milestone

  • May 4, 2026

Related Content

Weight-loss Drug Response Varies, But Why?

Study links DNA variants to weight loss and side effects

  • May 5, 2026

  • 2 min
Bridging the Diabetic Eye Care Divide

Study evaluates eye care utilization of diabetic patients in Northern Uganda, spotlighting limited health literacy and awareness as determining factors in care

  • May 1, 2026

  • 3 min
This Week’s Biopharma News: Wave of Antibody Approvals

FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars

  • April 28, 2026

  • 5 min